SCHEMBL183204

SCHEMBL183204

COc1ccc(-c2nc(N)nc3ccc(-c4ccc5c(c4)OCCO5)cc23)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.45
KIT P10721 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
DHFR P00374 2/20 0.43
SRC P12931 1/20 0.43
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ADORA1 P30542 2/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
MTOR P42345 1/20 0.41
PIK3CG P48736 1/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182832 1.00 ERN1 (0.45) ERN1KITCD274DHFRSRC
SCHEMBL182604 0.93 SRC (0.51) ERN1KITDHFRSRCADORA1
SCHEMBL182850 0.87 DHFR (0.53) DHFRKDM4EL3MBTL1ADORA1PIK3CD
SCHEMBL182854 0.82 PIK3CD (0.58) ERN1KITPIK3CDPIK3CAPIK3CB
SCHEMBL182570 0.82 PIK3CD (0.58) ERN1KITPIK3CDPIK3CAPIK3CB
SCHEMBL183022 0.81 SQSTM1 (0.48) KITDHFRKDM4EL3MBTL1ADORA1
SCHEMBL182874 0.80 PDGFRB (0.48) ERN1KITDHFRKDM4EL3MBTL1
SCHEMBL182897 0.80 ADORA1 (0.48) DHFRKDM4EL3MBTL1ADORA1PIK3CD
SCHEMBL182575 0.80 ADORA1 (0.52) DHFRKDM4EL3MBTL1ADORA1PIK3CD
SCHEMBL183029 0.78 PIK3CA (0.51) KITDHFRL3MBTL1ADORA1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed